A ten year review of depot medroxyprogesterone acetate contraceptive use at Rivers State University Teaching Hospital, South Nigeria


  • Esther I. Nonye-Enyidah Department of Obstetrics and Gynaecology, RSUTH, Port Harcourt, Rivers State, Nigeria
  • Terhemen Kasso Department of Obstetrics and Gynaecology, University of Port Harcourt Teaching Hospital, Port Harcourt, Rivers State, Nigeria




Acceptors, Contraception, Depo provera


Background: Depo Medroxyprogesterone Acetate (DMPA) also known as Depo provera is a long acting progestogen-only contraceptive injection used by women worldwide. It is given deep intramuscularly at interval of 3 months. It is easy to use, effective, safe, convenient and reversible. Objective was to determine the prevalence of DMPA contraceptive method and profile of its acceptors at the RSUTH.

Methods: This was a retrospective study of 271 clients attending family planning clinic at the RSUTH from 1st January, 2008 - 31st December, 2017. Their records were retrieved from the clinic and reviewed. Data was extracted, coded and analyzed using the statistical package for social sciences (SPSS) IBM version 25.0 (Armonk, NY).

Results: The prevalence rate of DMPA contraceptive among contraceptive acceptors at the RSUTH within the study period was 14.3 %. The modal age group was 30-34 years accounting for 103 (38.0%). Age range was 20-51 years. Two hundred and sixty eight (98.9%) had formal education. Majority of the clients had secondary level of education 209 (77.1 %). Of the 271 acceptors of DMPA, 175 (64.6%) were multipara. Most of the clients were married 259 (95.6%) and of Christian religion 265 (97.8%). Clinical personnel were the commonest source of information, accounting for 228 (84.1%).

Conclusions: The prevalence of DMPA use over the study period was low. There is need for more counseling and enlightenment campaign to encourage our women to use this effective and safe method of contraception.


Reshi P. Contraception: What’s new? Literature review. Inter J Obstetr Gynaecol. 2009;11:1.

Abasiattai AM, Udoma EJ, Ukeme E. Depot medroxyprogesterone injectable contraception at the Uyo Teaching Hospital, Uyo. Ann African Med. 2010;9(2):81-5.

Burkman R, Amnon B. Contraception and Family Planning. In: Decheney AH (Ed.). Current Diagnosis and Treatment Obstetrics and Gynaecology, Lange Medical Book. New York: McGraw-Hill Companies; 2013:928-947.

Adeyemi AS, Adekanle DA. Progestogen-only injectable contraceptive: Experience of women in Osogbo, Southwestern Nigeria. Ann Afr Med. 2012;11: 27-31.

Finer LB, Zolna MR. Unintended pregnancy in the United States: incidence and disparities. Contraception. 2011;84(5):478-85.

Wilailak S, Vipupinya C, Suraseranivong V, Chotivanich K, Kietpeerakool C, Tanapat Y McGraw-Hill Companies, et al. Depot Medroxyprogesterone Acetate and Epithelial Ovarian Cancer: A Multicentre Case-Control Study. BJOG. 2012;119:672- 7.

Okpere E. Contraception and family. In: Okpere E (Ed.). Clinical Gynecology. Benin: Uniben Press; 2005:244-274.

Li CI, Beaber EF, Tang MT, Porter PL, Daling JR, Malone KE. Effect of Depot-Medroxproge- sterone Acetate on Breast Cancer Risk among Women 20 to 44 Years of Age. Cancer Research. 2012;72:28-35.

Ezegwui HU, Ikeako LC, Obiora-Okafor NC. The Use of Depot Medroxyprogesterone Acetate Injectable Contraception in Enugu, Nigeria. Nigerian Medical J. 2012;21:266-71.

Darroch JE, Singh S. Trends in contraceptive need and use in developing countries in 2003, 2008, and 2012: an analysis of national surveys. Lancet. 2013;381(9879):1756-62.

Jacobstein R, Polis CB. Progestin-only contraception: Injectables and implants. Best Pract Res Clin Obstet Gynaecol. 2014;28:795-806.

World Health Organisation. The World Health Report 2013: Research for universal health coverage. Geneva: WHO; 2013.

Nonye-Enyidah Esther, Ejikem Mazi EC. Profile of intrauterine contraceptive device acceptors at the Rivers State University Teaching Hospital, southern Nigeria. World J Advanced Res Reviews. 2019;4(2):96-101.

National Population Commission, ICF International. Nigeria Demographic and Health Survey 2013. Abuja, Nigeria, and Rockville, Maryland, USA: NPC and ICF International; 2014:97.

Akadri AA, Odelola OI. Progesterone-only injectable contraceptive. Acceptor prevalence and client experience at Sagamu, Nigeria. Nigeria Postgraduate Medical J. 2017;24:178-81.

Ojule JD, Oriji VK, Okongwu C. A five year review of the complications of progestogen only injectable contraceptive at the University of Port Harcourt Teaching Hospital. Niger J Med. 2010;19:87-95.

Meka IA, Okwara EC, Meka AO. Contraception among bankers in an urban community in Lagos State, Nigeria. Pan Afr Med J. 2013;14:80.

Adeyemo AR, Oladipupo A, Omisore AO. Knowledge and practice of contraception among women of reproductive ages in South West Nigeria. Inter J Engin Sc. 2012;1(2):70-6.

Chigbu B, Onwere S, Aluka C, Kamanu C, Okoro O, et al. Contraceptive Choices of Women in Rural Southeastern Nigeria. Niger J Clin Pract. 2010;13:195-9.

Balogun, OR, Raji HO. Clinical Experience with Injectable Progestogen-Only Contraception at University of Ilorin Teaching Hospital: A Five-Year Review. Niger Postgrad Med J. 2009;16:260-3.

Igwegbe AO, Ugboaja JO. Clinical Experience with Injectable Progestogen-Only Contraceptives at Nnamdi Azikiwe University Teaching Hospital, Nnewi, Nigeria. J Med Med Sci. 2010;1:345-9.

Olugbenga-Bello AI, Abodunrin OL, Adeomi AA. Contraceptive practices among women in rural communities in South-Western Nigeria. Global J Med Res. 2011;11:1-9.






Original Research Articles